期刊文献+

那格列奈联合卡托普利治疗糖尿病肾病的临床研究 被引量:2

Therapeutic Effect of Nateglinide Combined with Captopril for Treatment of Diabetic Nephropathy
原文传递
导出
摘要 目的探讨那格列奈联合卡托普利治疗2型糖尿病肾病患者的临床疗效。方法 92例糖尿病肾病(Mogensen分期Ⅲ-Ⅳ期)患者,随机分为2组,试验组47例,那格列奈加卡托普利联合治疗;对照组45例,那格列奈治疗每日3次。疗程均为6周,观察治疗前后两组患者空腹血糖(FBG)、餐后2h血糖(2hBG)、糖化血红蛋白(HbA1c)、24h尿蛋白定量、血尿素氮(BUN)、肌酐(SCr)及血压的变化。结果对照组FBG、2hBG、HbA1c、24h尿蛋白定量均有下降,与治疗前比较差异有统计学意义(P<0.05),而BUN、SCr和血压与治疗前比较无明显变化;实验组在FBG、2hBG、HbA1c、24h尿蛋白定量、BUN、SCr和血压等方面均有下降,较治疗前有明显差异(P<0.05);治疗后,实验组在24h尿蛋白定量、BUN、SCr和血压4个指标优于对照组,差异有统计学意义(P<0.05)。结论那格列奈联合卡托普利治疗糖尿病肾病可有效控制血糖,改善肾脏功能。 Objective To evaluate the efficacy of nateglinide combined with captopril in patients with diabetic nephropathy.Methods Totally 92 patients with diabetic nephropathy(by Mogensen's stages:Ⅲ-Ⅳ)were randomly divided into 2 groups,47 patients in the trial group were treated by nateglinide combined with captopril injection.The other 45 patients in the control group were treated by nateglinide injection thrice daily.Both groups were under treatment for six weeks as a course,and the values of fasting blood glucose(FBG),postprandial 2h plasma glucose(2hBG),glycosylated hemoglobin(HbA1c),24h urinary protein,blood urea nitrogen(BUN),creatinine(SCr)and blood pressure before and after the treatment were observed.Results In control group FBG,2hBG,HbA1c,24h urine protein were decreased compared with that before treatment was significantly(P0.05),while BUN,SCr,and blood pressure showed no change;the experimental group in FBG,2hBG,HbA1c,24h urinary protein,BUN,SCr and blood pressure have declined significantly different than those before treatment(P0.05);after treatment,24h urine protein,BUN,SCr and blood pressure of the trial group were better than the control group,the difference was statistically significant(P0.05).Conclusion Nateglinide combined with captopril in treatment of diabetic nephropathy can effectively control blood sugar,improve kidney function.
作者 徐广成
出处 《医药论坛杂志》 2010年第22期53-56,共4页 Journal of Medical Forum
关键词 那格列奈 卡托普利 糖尿病肾病 Nateglinide Captopril Diabetic nephropathy
  • 相关文献

参考文献13

  • 1朱晓蓉,杨金奎.肾素-血管紧张素系统阻断治疗糖尿病肾病新进展[J].中国处方药,2009,8(12):39-41. 被引量:2
  • 2杨霓芝,刘旭生.糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007,41(7):7-8. 被引量:1181
  • 3唐彬,李斌,吴沃栋.2型糖尿病合并微血管病变危险因素分析[J].中国慢性病预防与控制,2002,10(1):41-41. 被引量:11
  • 4Romano Nosadini. Blood glucose in relation to blood pressure control as risk factors in the progression of renal damage in type 2 diabetes [ J ]. International Congress Series ,2003,1253:295-299.
  • 5王战建,刘珊.糖尿病肾病发病机制的研究进展[J].国际泌尿系统杂志,2006,26(5):693-696. 被引量:41
  • 6廖二元 超楚生.内分泌学[M].北京:人民卫生出版社,2001.610-611.
  • 7Houlihan CA,Akdeniz A,Tsalamandris C, et al. Urinary transforming growth factorbeta excretion in patients with hypertension,type 2 diabetes, and elevated albumin excretion rate: Effects of angiotensin receptor blockade and sodium restriction [ J ]. Diabetes Care, 2002,25 ( 6 ) : 1072-1077.
  • 8Agarwal IR,Siva S, Dunn SR, et al. Add -on angiotensin II receptor bloekade lowers urinary transf- orming growth factor-beta levels[ J ]. Am J Kidney Dis,2002, 39(3) :486-492.
  • 9Chachin M,Yamada M,Fujita A,et al. Nateglinide,a D -phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic be- ta - cell - type K(ATP) channels[J]. J Pharmacol Exp Ther,2003,304 ( 3 ) : 1025-1032.
  • 10Hu S, Wang S, Dunning BE. Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta - cell K (ATP) channels [ J ]. J Pharmacol Exp Ther, 1999,291 ( 3 ) : 1372 - 1379.

二级参考文献12

  • 1胡俊斌,魏文宁,丁桂芝,袁莉,刘仲萍.糖尿病患者凝血与纤溶状态初探[J].中华内分泌代谢杂志,1996,12(2):118-119. 被引量:32
  • 2Tsilibary EC.Microvascular basement membranes in diabetes mellitus.J Patho1,2003,200(4):537 -46.
  • 3Jensen LJ,Ostergard J,Flyvbjerg A.AGE-RAGE and AGE Cross -link interaction:important players in the pathogenesis of diabetic kidney disease.Horm Metab Res,2005,37 suppl 1:26 -34.
  • 4Wautier JL,Schmidt AM.Protein glycation:a firm link to endothelial cell dysfunction.Circ Res,2004,95 (3):233-8.
  • 5Banerjec S,Ghosh US,Saha SJ.Role of GFR estimation in assessment of the status of nephropathy in type 2 diabetes mellitus.J Assoc Physicians India,2005,53:181-4.
  • 6Jin Y,Moriya T,Tanaka K,et al.Glumerular hyperfiltration in no -proteinuric and non-hypertensive Janpanese type 2 diabetic patients Diabetes Rrs Clin Pract,2005:23.
  • 7Schena FP,Gesualdo L.Pathogenetic mechanisms of diabetic nephropathy.J AM Soc Nephrol.2005 , 16 Suppl 1:S30 -3.
  • 8Wolf G,Chen S,Ziyadeh FN.From the periphery of glumerular capillary wall toward the center of disease:podocyte injury comes of age in diabetic nephropathy.Diabetes,2005,54(6):1626 -34.
  • 9Flyvbjerg A,Khatir DS,Jensen LJ,et al.The involvement of growth hormone (GH),insulin-like growth factor (IGFs) and vascular endothelial growth factor (VEGF) in dibetic kindney disease.Curr Pharm Des,2004,10(27):3385 -94.
  • 10Miller-Kasprzak E,Niemir ZI,Czekalski S.The role of platelet-derived growth factor A(PDGF-A) in hypertension and renal disease.Pol Merkuriusz Lek,2004,16 (94):403-5.

共引文献2197

同被引文献22

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部